Chief Executive Officer

Anya is a clinical research scientist with expertise in child, adolescent, and adult psychiatry. Her work focuses on the safety and therapeutic potential of ketamine, MDMA, and classic psychedelics for treating eating disorders, PTSD, and suicidality.

Full Biography ↗

Chief Scientific Officer

Reid is a board-certified psychiatrist, IFS therapist, and adjunct professor of psychiatry with expertise in eating disorders. He has led over 250 clinical trials to date, including pivotal Phase 2 and 3 psychedelic studies sponsored by MAPS, Cybin, and MindMed.

Full Biography ↗

Chief Clinical Officer

Jamo is a board-certified psychiatrist, contemplative psychotherapist, and adjunct clinical assistant professor of psychiatry. Her work focuses on ketamine- and psychedelic-assisted psychotherapy for child, adolescent, and adult mental health.

Full Biography ↗

Chief Impact Officer

Miriam is a trauma‑informed psychedelic facilitator and human development specialist. Her work centers on ethical, inclusive, and community‑based healing practices that foster spirituality, mental health, and social well-being across the lifespan.

Full Biography ↗